Pregled bibliografske jedinice broj: 180556
Chromogranin A as a marker of osteolysis in Stage D3 prosatte cancer patients
Chromogranin A as a marker of osteolysis in Stage D3 prosatte cancer patients // Book of Abstracts, 13th International Prostate Cancer Update / E. David Crawford (ur.).
Denver (CO): icpme, 2003. str. 91-91 (predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 180556 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Chromogranin A as a marker of osteolysis in Stage D3 prosatte cancer patients
(HRPC, cytotoxic therapy, docetaxel plus estm, conversion of hormone refractory to hormone hypersensitive disease)
Autori
Novosel, Sunčica ; Kovačić, Ksenija ; Ahel, Zaky ; Kraljić, Ivo ; Kusuć, Zvonko ; Tarle, Marko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Book of Abstracts, 13th International Prostate Cancer Update
/ E. David Crawford - Denver (CO) : Icpme, 2003, 91-91
Skup
13th International Prostate Cancer Update
Mjesto i datum
Vail (CO), Sjedinjene Američke Države, 19.02.2004. - 23.02.2004
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Osteolysis; ostaoblastic lesions; vicious cycle; PTH level; bisphosphonates
(13th International Prostate Cancer Update)
Sažetak
Viciuos cycle involving osteoblasts, osteoclasts and prosate cancer tumors cells in bone, together with several promotors, has been examined. It apprears the among them the progression to osteolysis is best described by chromogranin A concentration with the lead time od about 6 months. In such HRPC several cytotoxic combinations were examined and phase II docetaxel/estm is the therapy of choice.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
